Metastatic Urothelial Cancer Active Not Recruiting Phase 3 Trials for Tremelimumab (DB11771)

IndicationStatusPhase
DBCOND0066157 (Metastatic Urothelial Cancer)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03682068Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerTreatment